Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [912]

The potential of PARP inhibitors in new cancer groups and in combination with...

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Dr Joel Neal - Stanford University, Stanford, USA

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )

A phase II study of bemcentinib with pembrolizumab in patients with advanced...

Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Pembrolizumab increases long-term survival in patients with advanced NSCLC

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Pembrolizumab increases long-term survival in patients with advanced NSCLC ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Expanding clinical trial eligibility criteria: Risks and solutions

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Expanding clinical trial eligibility criteria: Risks and solutions ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Carfilzomib and irinotecan in relapsed small cell lung cancer

Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA

Carfilzomib and irinotecan in relapsed small cell lung cancer ( Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA )

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients...

Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )

Understanding eligibility criteria for clinical trials to increase study size

Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills...

Understanding eligibility criteria for clinical trials to increase study size ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )

Expanded clinical trial inclusion criteria would double the percentage of...

Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills...

Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials ( Dr R. Donald Harvey - Winship Cancer Institute of Emory University, Druid Hills, Georgia )

Clinical and translational results from the NEOSTAR study: Treating early-stage...

Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston...

Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as...

Dr Edward B. Garon - UCLA, Los Angeles, USA

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )

Comment: The success of immunotherapy means we have to change our mindset as we...

Dr David Graham and Dr Edward B. Garon

Comment: The success of immunotherapy means we have to change our mindset as we treat patients ( Dr David Graham and Dr Edward B. Garon )

More from ecancer